RAC - Charts & Price Action, page-13042

IMO a critically important qualifier is to carry out own research and keep up to date on what the company is doing, what their strategy is, what is happening in the biotech/pharma industries and in the general stock market, what the risks are (what could go wrong), what the likely time horizon is (i.e. the amount of patience needed), what the possible downside is (i.e. just how scary potential downside may be, potential loss), what the possible execution/exit strategies are for the company - e.g. partnership/out-licensing, buyout (and the potential upside/profit for each), potential tax implications for an investment, your own strategies for buying - holding - selling, alternative investments, diversification strategies, whether to seek professional advice.


This is all important for decision making, particularly when markets are in volatile territory (although an upside to volatility is opportunity - but this requires conviction). Conviction can't be borrowed -



My latest post is here ( Post #:62409754 ), although this doesn't cover partnership/out-licensing scenarios and effort should be put into understanding potential upside for partnership/out-licensing scenarios.